The developments at Holland Capital in 2024 reflect our strong ambitions
Amsterdam/ Düsseldorf, 30th of December 2024 –The developments at Holland Capital in 2024 reflect our strong ambitions. Guided by a focused investment strategy, we continued to actively engage in the high-growth markets of Technology, Healthcare, and Agrifood. Reflecting on a successful year, we completed several key transactions and further strengthened our team.
2024 achievements
- The launch of our fund, Holland Capital Growth and Buy-Out Fund V
- Number of deals in the Netherlands: 5
- Number of add-on acquisitions in the Netherlands: 13
- Number of add-on acquisitions in Germany: 2
- Number of exits: 2
- Number of new colleagues: 4
Sector focus and an entrepreneurial hands-on approach: With specialized sector teams, we focus on the sectors of Healthcare, Technology, and Agrifood, both within the Growth & Buy-out and Venture & Growth segments. We understand the dynamics and opportunities in these sectors and have an extensive network. Holland Capital is not a passive investor; we work closely with management to define and execute strategies. Where needed, our operational team also contributes hands-on to the realization of specific projects within the company.
Which companies would we like to connect with?
- Sector: Technology, Healthcare, and Agrifood
- Positive outlook: Significant growth potential, both autonomous and buy-and-build
- Growth & Buy-out:
- Healthy profitability: cash flow from operations (EBITDA) between EUR 1 – 10m
- Smaller companies: considered as add-on acquisitions for our existing portfolio companies
- Larger companies: considered together with a co-investor
- Venture & Growth:
- Start-ups and scale-ups: EBITDA EUR <1m
- Cash flow negative (in an accelerated growth scenario)
- Revenue EUR 0 – 5m
What to expect from us?
- Flexible approach to transaction structures: We strive to adapt each structure to the needs of the company and its shareholders. Depending on the type of investment, Holland Capital either provides growth capital and/or acquires existing shares. We are flexible regarding the final capital structure: both majority and minority stakes are possible.
- Deal certainty and an efficient process: Thanks to our sector expertise, we are able to quickly assess a business model and put a fair price on the table. Since the partnership with the entrepreneur and/or the management team is the cornerstone of our investment, we devote above-average attention to ensuring the process is completed efficiently, in the right spirit, and with mutual respect for both parties.
- Transparency towards advisors: We appreciate it when advisors involve us early in discussions with entrepreneurs and/or management teams. In such cases, we always ensure that the advisor’s interests are well safeguarded throughout the process. The advisor retains the flexibility to decide whether to represent the sell-side or buy-side in a potential transaction.
About Holland Capital
Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and fosters an open, sustainable, and professional relationship with the management teams of the invested companies, aiming for mutual growth. With offices in Amsterdam and Düsseldorf, Holland Capital focuses on Healthcare, Technology, and Agrifood-Tech sector.
Sirius Medical announces CE mark for Pintuition: a non-radioactive localization system to improve breast cancer surgery
Sirius Medical announces CE mark for Pintuition: a non-radioactive localization system to improve breast cancer surgery Eindhoven, June 16, 2020 – Sirius Medical, a MedTech startup, announced that it has received CE mark approval for Sirius Pintuition. With its debut...
Sirius Medical ontvangt CE-markering voor Pintuition: een niet radioactief lokalisatiesysteem ter verbetering van borstkankeroperaties
Sirius Medical ontvangt CE-markering voor Pintuition: een niet-radioactief lokalisatiesysteem ter verbetering van borstkankeroperaties Eindhoven, 16 Juni 2020 Sirius Medical, een medtech startup, kondigt aan dat het CE-markering heeft ontvangen voor Sirius...
CytoSMART to donate 100 live-cell imaging systems to assist COVID-19 researchers
CytoSMART to donate 100 live-cell imaging systems to assist COVID-19 researchers Eindhoven, The Netherlands - 22 April 2020, - CytoSMART Technologies is to donate 100 mini live-cell imaging systems to researchers in high containment labs worldwide. Labs working to...
Yenlo benoemd tot Platinum VAR, de hoogste WSO2 Reseller status
Yenlo benoemd tot Platinum VAR, de hoogste WSO2 Reseller statusYenlo is benoemd tot WSO2 Platinum Value-Added Reseller als erkenning voor de behaalde successen en het leveren van de beste opensource integratie- en API-managementoplossingen gebaseerd op het WSO2...
Yenlo Achieves Highest WSO2 Reseller Status as a Platinum VAR
Yenlo Achieves Highest WSO2 Reseller Status as a Platinum VAR Yenlo was named a WSO2 Platinum Value-Added Reseller in recognition of its success in growing global customer adoption and delivering best-in-class open source integration and API management solutions based...
Portfolio company Inno4Life sold to the Swiss company Dec Group
Portfolio company Inno4Life sold to the Swiss company Dec Group Amsterdam, April 16, 2020 - Earlier this month, Inno4Life, a manufacturer of machines for the pharmaceutical industry, was sold to the Swiss Dec Group. Inno4Life's management will remain actively involved...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl